Survival Analysis of Radiation Therapy in Ovarian Cancer: A SEER Database Analysis

Table 2

Univariable Cox regression analysis for patients with ovarian cancer before and after propensity score matching analysis.

		Before PSM		After PSM
		Unadjusted HR (95% CI)	value	Unadjusted HR (95% CI)	value
Age, y	≤40	Ref.		Ref.
	40–60	0.46 (0.41–0.52)	<0.001	0.58 (0.33–1.01)	0.056
	>60	1.78 (1.69–1.87)	<0.001	1.88 (1.45–2.42)	<0.001
Race	White	Ref.		Ref.
	Black	1.26 (1.16–1.36)	<0.001	1.22 (0.79–1.88)	0.364
	Others	0.79 (0.72–0.86)	<0.001	0.64 (0.44–0.93)	0.021
	UNK	0.25 (0.13–0.46)	<0.001	0 (0-NR)	0.946
Marital status	Married	Ref.		Ref.
	Never married	0.97 (0.91–1.04)	0.405	0.92 (0.66–1.27)	0.600
	Other	1.53 (1.45–1.62)	<0.001	1.37 (1.02–1.84)	0.035
	UNK	0.99 (0.88–1.12)	0.874	1.14 (0.50–2.60)	0.746
Insurance	No	Ref.		Ref.
	Yes	1.04 (0.92–1.18)	0.566	0.29 (0.13–0.61)	0.001
	UNK	1.07 (0.85–1.34)	0.583	0.44 (0.11–1.71)	0.238
Laterality	Single	Ref.		Ref.
	Bilateral	1.94 (1.84–2.03)	<0.001	1.45 (1.11–1.89)	0.007
	UNK	2.84 (2.58–3.12)	<0.001	4.10 (2.78–6.04)	<0.001
Tumor size, mm	≤50	Ref.		Ref.
	50–100	0.93 (0.86–1.00)	0.040	0.96 (0.64–1.46)	0.862
	100–200	0.75 (0.70–0.81)	<0.001	1.30 (0.87–1.95)	0.193
	>200	0.72 (0.64–0.81)	<0.001	1.43 (0.76–2.68)	0.267
	UNK	1.30 (1.21–1.39)	<0.001	1.58 (1.07–2.33)	0.021
Pathology	Epithelial	Ref.		Ref.
	Not epithelial	1.10 (1.04–1.17)	<0.001	1.62 (1.26–2.08)	<0.001
Grade	G1	Ref.		Ref.
	G2	2.54 (2.12–3.04)	<0.001	1.24 (0.42–3.62)	0.697
	G3	5.53 (4.70–6.50)	<0.001	3.53 (1.44–8.66)	0.006
	G4	5.42 (4.60–6.38)	<0.001	3.62 (1.45–9.06)	0.006
	UNK	4.33 (3.67–5.11)	<0.001	3.99 (1.61–9.90)	0.003
SEER combined summary stage	Local	Ref.		Ref.
	Regional	2.67 (2.33–3.05)	<0.001	4.59 (1.82–11.60)	0.001
	Distant	9.07 (8.04–10.23)	<0.001	14.35 (5.89–34.97)	<0.001
	UNK	5.91 (4.59–7.62)	<0.001	9.40 (2.52–35.04)	0.001
AJCC stage	I	Ref.		Ref.
	II	3.10 (2.73–3.53)	<0.001	6.64 (3.11–14.19)	<0.001
	III	6.85 (6.23–7.53)	<0.001	9.69 (4.87–19.26)	<0.001
	IV	10.71 (9.71–11.82)	<0.001	16.62 (8.39–32.92)	<0.001
	UNK	6.26 (5.21–7.53)	<0.001	11.00 (4.55–26.59)	<0.001
T	T0	Ref.		Ref.
	T1	0.16 (0.09–0.30)	<0.001	0.20 (0.03–1.48)	0.114
	T2	0.57 (0.32–1.04)	0.065	0.67 (0.09–4.88)	0.693
	T3	1.11 (0.61–2.01)	0.730	1.19 (0.17–8.49)	0.865
	Tx/NA	1.11 (0.61–2.03)	0.737	1.72 (0.23–12.67)	0.595
N	N0	Ref.		Ref.
	N1	1.83 (1.73–1.93)	<0.001	1.65 (1.25–2.16)	<0.001
	Nx/NA	2.73 (2.51–2.96)	<0.001	2.71 (1.86–3.95)	<0.001
M	M0	Ref.		Ref.
	M1	2.69 (2.56–2.83)	<0.001	2.82 (2.19–3.64)	<0.001
	NA	1.95 (1.32–2.89)	0.001	2.51 (1.03–6.15)	0.043
Surgery	No	Ref.		Ref.
	Yes	0.14 (0.11–0.16)	<0.001	0.16 (0.11–0.23)	<0.001
Radiation	No	Ref.		Ref.
	Yes	2.70 (2.34–3.12)	<0.001	1.72 (1.33–2.22)	<0.001
Chemotherapy	Yes	Ref.		Ref.
	No/UNK	0.76 (0.72–0.81)	<0.001	1.21 (0.90–1.64)	0.208
Therapy	Non-R	Ref.		Ref.
	R	6.83 (4.68–9.97)	<0.001	4.90 (2.75–8.74)	<0.001
	R + S	2.77 (1.61–4.77)	<0.001	2.10 (1.18–3.74)	0.012
	R + C	5.50 (4.10–7.38)	<0.001	4.06 (1.48–11.12)	0.007
	S + C + R	1.97 (1.62–2.38)	<0.001	1.53 (1.17–2.01)	0.002
CA125, U/mL	Normal	Ref.		Ref.
	Elevated	3.23 (2.88–3.62)	<0.001	3.77 (2.22–6.38)	<0.001
	Borderline	1.66 (0.78–3.51)	0.186	—	—
	UNK	2.28 (2.02–2.59)	<0.001	3.67 (2.08–6.47)	<0.001

Abbreviations: PSM: propensity score matching; HR: hazard ratio; CI: confidence interval; Ref.: reference; UNK: unknown; NA: not applicable; R: radiotherapy; S: surgery; C: chemotherapy.